ClinicalTrials.gg
CompletedNCT06354257Updated Aug 26, 2025Results posted

A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age

A Phase 1 interventional study of Microgynon and GSK3036656 in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 1 site in Spain. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Tuberculosis by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Tuberculosis · GlaxoSmithKline.

Enrollment
18th of 21
20 · median 50
Started
2024
the only one that year
Phase 1
8 of 21
1 open now
Registered
20th of 21
by date

Among the 21 studies in Tuberculosis by GlaxoSmithKline, this one is the 18th largest by enrollment, is the only one that started in 2024, is one of 8 in phase 1, and was the 20th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

1 of the 21 studies in Tuberculosis by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Tuberculosis by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to provide data showing if there are any effects of GSK3036656 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which will help inform future studies on suitable contraceptive measures to be used.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Oral contraceptive
  • GSK3036656
  • Fixed sequence
  • Ethinyl Estradiol
  • Levonorgestrel
  • Drug interaction
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Age:

  1. Participant was 18 to 65 years of age, inclusive, at the time of signing the .

    Type of Participant and Disease Characteristics:

  2. Participants were healthy or compensated, as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ).
  3. was >= 75 mL/min.
  4. Echocardiogram was normal or showed normal left ventricular function; at most trace to mild valvular regurgitation was allowed, with no valvular stenosis.

    Weight:

  5. Body weight was >= 45.0 kg (99 lbs), and was within the range 18.5 to 31.0 kg/m² (inclusive).

    Sex:

  6. Female participants were of Nonchildbearing Potential (WONCBP).

    Women in the following categories were considered WONCBP:

    Permanently sterile due to one of the following procedures:

    1. Documented hysterectomy.
    2. Documented bilateral salpingectomy.
    3. Documented bilateral oophorectomy.

    females. A postmenopausal state was defined as no menses for 12 months without an alternative medical cause.

    • A high follicle-stimulating hormone (FSH) level in the postmenopausal range could have been used to confirm a postmenopausal state in women not using hormonal or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with >1 FSH measurement was required within the screening period.
    • Females on HRT and whose menopausal status was in doubt discontinued HRT >= 30 days prior to the start of Treatment Period 1 to allow confirmation of postmenopausal status before study enrolment.

    Informed Consent:

  7. Participant was capable of giving signed informed consent, which included compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

Exclusion Criteria:

Medical History:

  1. History of known cardiac valve abnormalities.

    Laboratory Assessments:

  2. Presence of surface antigen at Screening or within 3 months prior to starting study treatment.
  3. Positive antibody test result at Screening or within 3 months prior to starting study treatment, and positive on reflex to hepatitis C RNA.
  4. Positive -1 and -2 antigen/antibody immunoassay at Screening.
  5. (ALT) > 1.5×. A single repeat of ALT was allowed within a single screening period to determine eligibility.
  6. > 1.5×ULN (isolated bilirubin > 1.5×ULN was acceptable if bilirubin was fractionated and direct bilirubin was \< 35%).
  7. Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should have precluded participation in the study of an compound.
  8. Participants with \< 8.0 g/dL.
  9. Any Grade 2 to 4 laboratory abnormality at Screening-except creatine phosphokinase, lipid abnormalities, and ALT (as above)-excluded a participant unless the investigator provided a compelling explanation and had sponsor assent. A single repeat of any laboratory abnormality was allowed within a single screening period.
  10. Positive test result for drugs of abuse (including marijuana), alcohol, or cotinine at Screening or before the first study dose.

    Prior/Concomitant Therapy:

  11. Participants were unable to refrain from using prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's wort), within 7 days prior to the first dose and throughout the study.

    Levothyroxine and omeprazole were allowed if participants had been on a stable dose for >= 1 month prior to Treatment Period 1 and maintained the same dose. Microgynon was administered >= 1 hour after levothyroxine or omeprazole. Other medications were allowed on a case-by-case basis with medical monitor and GSK ganfeborole team approval.

  12. Participants received any vaccine within 30 days prior to study treatment.
  13. Participants were unwilling to abstain from excessive consumption of caffeine, grapefruit, grapefruit juice, Seville oranges, blood oranges, pomelos, or their juices within 7 days prior to first dose through study end.
  14. Participants who had undergone IVF or assisted reproductive techniques within 9 months prior to screening, were currently participating, or planned such procedures during the following year were excluded.

    Prior/Concurrent Clinical Study Experience:

  15. Participants had taken part in another clinical study within 30 days, 5 half-lives + 10 days, or 2× duration of the investigational product's biological effect (whichever was longer).
  16. Study participation resulted in donation of blood or blood products > 500 mL within 56 days.

    Diagnostic Assessments:

  17. Significant arrhythmia or ECG findings, in the opinion of the investigator or GSK Medical Monitor, would have interfered with participant safety.
  18. Exclusion criteria for screening ECG:

    Heart rate \< 50 or > 100 bpm

    interval > 450 ms

    Other Exclusion Criteria:

  19. Participants with vitiligo.
  20. Participants with hypertension or Type 2 diabetes that could not be controlled with diet and exercise alone.
  21. History of regular alcohol consumption within 6 months of the study, defined as an average weekly intake > 14 units.
  22. Use of tobacco- or nicotine-containing products within 3 months prior to Screening.
  23. History of sensitivity to any study medications or components, or any allergy that, in the investigator's or medical monitor's opinion, participation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Combined Participants Group

    Participants received a dose of Microgynon \[0.03 mg Ethinyl Estradiol (EE)/0.15 mg Levonorgestrel (LNG)\] on Day 1 of Treatment Period 1. In Treatment Period 2, they received GSK3036656 40 mg on Day 4 followed by GSK3036656 20 mg once daily from Day 5 to Day 14. In Treatment Period 3, participants received Microgynon (EE/LNG) along with GSK3036656 20 mg on Day 15, followed by GSK3036656 20 mg once daily from Day 16 to Day 17.

    Drug: Microgynon · Drug: GSK3036656

Interventions

  • DrugMicrogynon

    Participants received 1 dose of Microgynon (0.03 mg EE/0.15 mg LNG) on Day 1 of Treatment Period 1 and 1 dose co-administered with GSK3036656 20 mg on Day 15 of Treatment Period 3.

  • Participants received 1 loading dose of 40 mg on Day 4 and a dose of 20 mg on Days 5 to 14 once daily in Treatment Period 2. In Treatment Period 3, participants received one 20 mg dose along with Microgynon (0.03 mg EE/0.15 mg LNG) on Day 15 after which a 20 mg dose on Days 17 and 18 once daily.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG

    AUC(0-inf) is defined as the area under the concentration-time curve from time 0 extrapolated to infinity and was calculated by using a non-compartmental analysis.

    Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group

  2. Maximum Observed Plasma Concentration (Cmax) After a Single Dose of EE and LNG

    Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.

    Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group

Secondary outcomes

  1. AUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG

    AUC(0-tau) is defined as the area under the concentration-time curve over a dosing interval and was calculated by using a non-compartmental analysis.

    Time frame: At Day 15

  2. Cmax at Steady State of GSK3036656 With EE/LNG

    Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.

    Time frame: At Day 15

  3. Trough Plasma Concentration (Ctau) at Steady State of GSK3036656 With EE/LNG and GSK3036656 Alone

    Ctau is defined as the concentration reached by the drug immediately before the next dose is administered.

    Time frame: At Day 8, 10, 12, 15 and 16

  4. Time to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG

    Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.

    Time frame: At Day 15

  5. AUC Versus Time Curve (AUC[0-t]) of EE and LNG Alone and With GSK3036656

    AUC(0-t) is defined as area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration and was calculated by using a non-compartmental analysis.

    Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group

  6. Tmax of EE and LNG Alone and With GSK3036656

    Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.

    Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group

  7. Apparent Terminal Half-life (t1/2) of EE and LNG Alone and With GSK3036656

    t1/2 is defined as the time required by the plasma concentration to decline by 50% and was calculated by using a non-compartmental analysis.

    Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group

  8. Number of Participants With Serious Adverse Events (SAEs)

    A SAE is defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

    Time frame: From the signing of the informed consent form (a period starting up to 14 days before the first dose on Day 1) up to Day 18

  9. Number of Participants With Grade 3 or Higher Severity Adverse Events (AEs)

    The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity.

    Time frame: From Day 1 up to Day 18

  10. Number of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656

    The drug-related AEs were assessed by the investigator to be possibly, probably or definitely related to the study interventions.

    Time frame: From Day 1 up to Day 18

  11. Number of Participants Withdrawn From the Treatment Due to AEs

    Adverse events resulting in withholding of study intervention administration were included in this outcome measure.

    Time frame: From Day 1 up to Day 18

  12. Number of Participants Withdrawn From the Study Due to AEs

    Time frame: From Day 1 up to Day 18

  13. Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)

    PCI ECG values are defined as any ECG findings which, in the opinion of the investigator or medical monitor would interfere with the safety of the individual participant. The ECG measurements analyzed are PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

    Time frame: From Day 1 up to Day 18

  14. Number of Participants With Clinical Chemistry Laboratory Values of PCI

    The chemistry parameters analyzed are homocysteine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin, bilirubin, calcium, creatine kinase, potassium, protein, sodium, urea, and glucose. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

    Time frame: From Day 1 up to Day 18

  15. Number of Participants With Haematology Laboratory Values of PCI

    The analyzed hematology parameters are reticulocytes/erythrocytes, monocytes/leukocytes, erythrocytes, basophils/leukocytes, eosinophils/leukocytes, mean corpuscular hemoglobin, hematocrit, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

    Time frame: From Day 1 up to Day 18

  16. Number of Participants With Vital Signs Parameters of PCI

    The analyzed vital signs are systolic blood pressure, diastolic blood pressure, heart rate, body temperature, and respiration rate. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

    Time frame: From Day 1 up to Day 18

07

Results

Posted Aug 26, 2025

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneCombined Participants Group
Started20
Completed19
Not completed1
Withdrew: Withdrawal by subject1
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneCombined Participants Group
Started19
Completed18
Not completed1
Withdrew: Adverse event1
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneCombined Participants Group
Started18
Completed18
Not completed0

Outcome measures

PrimaryArea Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG

AUC(0-inf) is defined as the area under the concentration-time curve from time 0 extrapolated to infinity and was calculated by using a non-compartmental analysis.

Time frame:
At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Reported as:
Geometric mean · hour*picogram per milliliter (h*pg/mL)
Area Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG
hour*picogram per milliliter (h*pg/mL)Treatment Period 1: Microgynon GroupTreatment Period 3: Microgynon + GSK3036656 Group
EE, Day 1627.11 ± 53.0—
EE, Day 15—552.01 ± 51.0
LNG, Day 124651.76 ± 113.2—
LNG, Day 15—30334.48 ± 94.2
Statistical analysis
  • Treatment Period 1: Microgynon Group vs Treatment Period 3: Microgynon + GSK3036656 Group · Mixed Models Analysis · Geometric mean ratio: 0.88 · 90% CI 0.55 to 1.41One-sided tests (alpha=0.05) were used. 90% CIs for each ratio were compared to 0.8-1.25. No drug interaction is shown if CIs for AUC(0-inf) and Cmax of EE and LNG fall within 0.8-1.25.
  • Treatment Period 1: Microgynon Group vs Treatment Period 3: Microgynon + GSK3036656 Group · Mixed Models Analysis · Geometric mean ratio: 1.10 · 90% CI 0.98 to 1.23One-sided tests (alpha=0.05) were used. 90% CIs for each ratio were compared to 0.8-1.25. No drug interaction is shown if CIs for AUC(0-inf) and Cmax of EE and LNG fall within 0.8-1.25.
PrimaryMaximum Observed Plasma Concentration (Cmax) After a Single Dose of EE and LNG

Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.

Time frame:
At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Reported as:
Geometric mean · picogram per milliliter (pg/mL)
Maximum Observed Plasma Concentration (Cmax) After a Single Dose of EE and LNG
picogram per milliliter (pg/mL)Treatment Period 1: Microgynon GroupTreatment Period 3: Microgynon + GSK3036656 Group
EE, Day 150.86 ± 32.7—
EE, Day 15—48.96 ± 24.5
LNG, Day 12599.85 ± 46.8—
LNG, Day 15—2828.17 ± 45.3
Statistical analysis
  • Treatment Period 1: Microgynon Group vs Treatment Period 3: Microgynon + GSK3036656 Group · Mixed Models Analysis · Geometric mean ratio: 0.96 · 90% CI 0.85 to 1.09One-sided tests (alpha=0.05) were used. 90% CIs for each ratio were compared to 0.8-1.25. No drug interaction is shown if CIs for AUC(0-inf) and Cmax of EE and LNG fall within 0.8-1.25.
  • Treatment Period 1: Microgynon Group vs Treatment Period 3: Microgynon + GSK3036656 Group · Mixed Models Analysis · Geometric mean ratio: 1.08 · 90% CI 0.97 to 1.19One-sided tests (alpha=0.05) were used. 90% CIs for each ratio were compared to 0.8-1.25. No drug interaction is shown if CIs for AUC(0-inf) and Cmax of EE and LNG fall within 0.8-1.25.
SecondaryAUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG

AUC(0-tau) is defined as the area under the concentration-time curve over a dosing interval and was calculated by using a non-compartmental analysis.

Time frame:
At Day 15
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG
hour*nanogram per milliliter (h*ng/mL)Treatment Period 3: Microgynon + GSK3036656 Group
AUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG8372.42 ± 18.8
SecondaryCmax at Steady State of GSK3036656 With EE/LNG

Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.

Time frame:
At Day 15
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax at Steady State of GSK3036656 With EE/LNG
nanogram per milliliter (ng/mL)Treatment Period 3: Microgynon + GSK3036656 Group
Cmax at Steady State of GSK3036656 With EE/LNG600.62 ± 14.2
SecondaryTrough Plasma Concentration (Ctau) at Steady State of GSK3036656 With EE/LNG and GSK3036656 Alone

Ctau is defined as the concentration reached by the drug immediately before the next dose is administered.

Time frame:
At Day 8, 10, 12, 15 and 16
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentration (Ctau) at Steady State of GSK3036656 With EE/LNG and GSK3036656 Alone
ng/mLTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Day 8226.92 ± 17.9—
Day 10235.54 ± 27.5—
Day 12243.40 ± 21.9—
Day 15—251.26 ± 40.3
Day 16—254.91 ± 23.0
SecondaryTime to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG

Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.

Time frame:
At Day 15
Reported as:
Median · hour
Time to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG
hourTreatment Period 3: Microgynon + GSK3036656 Group
Time to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG0.95 (0.4 to 3.0)
SecondaryAUC Versus Time Curve (AUC[0-t]) of EE and LNG Alone and With GSK3036656

AUC(0-t) is defined as area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration and was calculated by using a non-compartmental analysis.

Time frame:
At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Reported as:
Geometric mean · h*pg/mL
AUC Versus Time Curve (AUC[0-t]) of EE and LNG Alone and With GSK3036656
h*pg/mLTreatment Period 1: Microgynon GroupTreatment Period 3: Microgynon + GSK3036656 Group
EE, Day 1447.10 ± 58.7—
EE, Day 15—363.00 ± 43.4
LNG, Day 121182.61 ± 84.3—
LNG, Day 15—23287.77 ± 91.3
SecondaryTmax of EE and LNG Alone and With GSK3036656

Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.

Time frame:
At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Reported as:
Median · hour
Tmax of EE and LNG Alone and With GSK3036656
hourTreatment Period 1: Microgynon GroupTreatment Period 3: Microgynon + GSK3036656 Group
EE, Day 10.967 (0.47 to 2.97)—
EE, Day 15—1.433 (0.45 to 3.05)
LNG, Day 10.967 (0.92 to 1.93)—
LNG, Day 15—0.967 (0.45 to 2.07)
SecondaryApparent Terminal Half-life (t1/2) of EE and LNG Alone and With GSK3036656

t1/2 is defined as the time required by the plasma concentration to decline by 50% and was calculated by using a non-compartmental analysis.

Time frame:
At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Reported as:
Median · hour
Apparent Terminal Half-life (t1/2) of EE and LNG Alone and With GSK3036656
hourTreatment Period 1: Microgynon GroupTreatment Period 3: Microgynon + GSK3036656 Group
EE, Day 119.180 (4.38 to 49.03)—
EE, Day 15—10.867 (3.14 to 29.39)
LNG, Day 141.315 (4.00 to 100.00)—
LNG, Day 15—34.697 (4.17 to 118.18)
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

A SAE is defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Time frame:
From the signing of the informed consent form (a period starting up to 14 days before the first dose on Day 1) up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Number of Participants With Serious Adverse Events (SAEs)000
SecondaryNumber of Participants With Grade 3 or Higher Severity Adverse Events (AEs)

The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Severity Adverse Events (AEs)
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Number of Participants With Grade 3 or Higher Severity Adverse Events (AEs)000
SecondaryNumber of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656

The drug-related AEs were assessed by the investigator to be possibly, probably or definitely related to the study interventions.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Number of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656000
SecondaryNumber of Participants Withdrawn From the Treatment Due to AEs

Adverse events resulting in withholding of study intervention administration were included in this outcome measure.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From the Treatment Due to AEs
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Number of Participants Withdrawn From the Treatment Due to AEs010
SecondaryNumber of Participants Withdrawn From the Study Due to AEs
Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From the Study Due to AEs
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Number of Participants Withdrawn From the Study Due to AEs010
SecondaryNumber of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)

PCI ECG values are defined as any ECG findings which, in the opinion of the investigator or medical monitor would interfere with the safety of the individual participant. The ECG measurements analyzed are PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
PR Interval, To Low000
PR Interval, To W/in Range or No Change201918
PR Interval, To High000
QRS Duration, To Low313
QRS Duration, To W/in Range or No Change171815
QRS Duration, To High000
QTcF Interval, To Low000
QTcF Interval, To W/in Range or No Change201918
QTcF Interval, To High000
SecondaryNumber of Participants With Clinical Chemistry Laboratory Values of PCI

The chemistry parameters analyzed are homocysteine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin, bilirubin, calcium, creatine kinase, potassium, protein, sodium, urea, and glucose. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Laboratory Values of PCI
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Homocysteine, To Low000
Homocysteine, To W/in Range or No Change191915
Homocysteine, To High103
ALT, To Low000
ALT, To W/in Range or No Change201918
ALT, To High000
AST, To Low000
AST, To W/in Range or No Change201615
AST, To High000
Direct Bilirubin, To Low000
Direct Bilirubin, To W/in Range or No Change201717
Direct Bilirubin, To High010
Bilirubin, To Low000
Bilirubin, To W/in Range or No Change201817
Bilirubin, To High000
Calcium, To Low000
Calcium, To W/in Range or No Change201918
Calcium, To High000
Creatine Kinase, To Low000
Creatine Kinase, To W/in Range or No Change201818
Creatine Kinase, To High010
Potassium, To Low000
Potassium, To W/in Range or No Change201615
Potassium, To High000
Protein, To Low000
Protein, To W/in Range or No Change201918
Protein, To High000
Sodium, To Low000
Sodium, To W/in Range or No Change201918
Sodium, To High000
Urea, To Low000
Urea, To W/in Range or No Change191918
Urea, To High100
Glucose, To Low000
Glucose, To W/in Range or No Change191818
Glucose, To High000
SecondaryNumber of Participants With Haematology Laboratory Values of PCI

The analyzed hematology parameters are reticulocytes/erythrocytes, monocytes/leukocytes, erythrocytes, basophils/leukocytes, eosinophils/leukocytes, mean corpuscular hemoglobin, hematocrit, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Haematology Laboratory Values of PCI
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Basophils/Leukocytes, To Low711
Basophils/Leukocytes, To W/in Range or No Change131716
Basophils/Leukocytes, To High000
Eosinophils/Leukocytes, To Low102
Eosinophils/Leukocytes, To W/in Range or No Change191415
Eosinophils/Leukocytes, To High040
Monocytes/Leukocytes, To Low000
Monocytes/Leukocytes, To W/in Range or No Change201717
Monocytes/Leukocytes, To High010
Erythrocytes, To Low050
Erythrocytes, To W/in Range or No Change201317
Erythrocytes, To High000
Reticulocytes/Erythrocytes, To Low000
Reticulocytes/Erythrocytes, To W/in Range or No Change191616
Reticulocytes/Erythrocytes, To High121
Mean Corpuscular Hemoglobin, To Low000
Mean Corpuscular Hemoglobin, To W/in Range or No Change201817
Mean Corpuscular Hemoglobin, To High000
Hematocrit, To Low000
Hematocrit, To W/in Range or No Change201817
Hematocrit, To High000
Hemoglobin, To Low000
Hemoglobin, To W/in Range or No Change201817
Hemoglobin, To High000
Lymphocytes, To Low000
Lymphocytes, To W/in Range or No Change201817
Lymphocytes, To High000
Neutrophils, To Low000
Neutrophils, To W/in Range or No Change201817
Neutrophils, To High000
Platelets, To Low000
Platelets, To W/in Range or No Change201817
Platelets, To High000
SecondaryNumber of Participants With Vital Signs Parameters of PCI

The analyzed vital signs are systolic blood pressure, diastolic blood pressure, heart rate, body temperature, and respiration rate. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.

Time frame:
From Day 1 up to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Parameters of PCI
ParticipantsTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
Diastolic Blood Pressure, To Low000
Diastolic Blood Pressure, To w/in Range or No Change201918
Diastolic Blood Pressure, To High000
Pulse Rate, To Low000
Pulse Rate, To w/in Range or No Change201918
Pulse Rate, To High000
Respiratory Rate, To Low000
Respiratory Rate, To w/in Range or No Change201918
Respiratory Rate, To High000
Systolic Blood Pressure, To Low000
Systolic Blood Pressure, To w/in Range or No Change201918
Systolic Blood Pressure, To High000
Temperature, To Low000
Temperature, To w/in Range or No Change201918
Temperature, To High000

Adverse events

Collected over Adverse Events were reported from Day 1 (first study dose) up to Day 18. Serious Adverse Events were reported from the signing of the informed consent form (a period starting up to 14 days before the first dose on Day 1) up to Day 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period 1: Microgynon Group0/20 (0%)0/20 (0%)4/20 (20%)
Treatment Period 2: GSK3036656 Group0/19 (0%)0/19 (0%)1/19 (5.3%)
Treatment Period 3: Microgynon + GSK3036656 Group0/18 (0%)0/18 (0%)1/18 (5.6%)
Most frequent other events
Most frequent other events
EventTreatment Period 1: Microgynon GroupTreatment Period 2: GSK3036656 GroupTreatment Period 3: Microgynon + GSK3036656 Group
HeadacheNervous system disorders4/200/191/18
ToothacheGastrointestinal disorders0/201/190/18

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Combined Participants Group
Mean53.6 ± 5.64
Sex: Female, Male
Sex: Female, Male(Participants)Combined Participants Group
Female20
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Combined Participants Group
WHITE20
08

Study locations

1 site
  • GSK Investigational Site
    Madrid, 28046, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jul 2024, 2 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 9, 2024
StartActual
Apr 5, 2024
Primary completionActual
Jul 1, 2024
CompletionActual
Jul 1, 2024
Results first posted
Aug 26, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06354257
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Apr 5, 2024
Primary completion
Jul 1, 2024
Completion
Jul 1, 2024
Results posted
Aug 26, 2025
Last update
Aug 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK656

Start the discussion